Skip to main content
Clinical Trials/JPRN-jRCTs031220199
JPRN-jRCTs031220199Active, not recruitingPhase 2

Efficacy and Safety of [11C]MeLeu as a novel PET probe in patients with pancreatic cancer

Yamazaki Kana0 sites20 target enrollmentStarted: July 8, 2022Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Active, not recruiting
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 18age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • 1.Subjects who are 18 years of age or older at the time of consent acquisition
  • 2.Subjects who have been confirmed to have pancreatic cancer by histopathological or clinical examination
  • 3.Subjects who have performed or are scheduled to perform [18F]FDG PET/CT by insurance within 30 days before or after the date of obtaining [11C]MeLeu PET/CT imaging, if [18F]FDG PET/CT imaging information is to be used
  • 4.Subjects whose Performance Status (ECOG PS) is 0 or 1
  • 5.Subjects who provide written informed consent

Exclusion Criteria

  • 1.Subjects who have severe or progressive complications or subjects who have a history of these complications and are judged by the investigator or co-investigator to be unsuitable for this study
  • 2.Subjects who have obvious abnormalities in physical and laboratory examinations (blood test and urinalysis) after obtaining the informed consent
  • 3.Subjects with drug addiction or alcohol addiction
  • 4.Subjects with mental illness or psychiatric symptoms who are judged to have difficulty in participating in this study
  • 5.Subjects who are unable or restricted from the tests specified in the research plan
  • 6.Subjects who are claustrophobic
  • 7.Subjects who are considered to be inappropriate to participate in this study by the investigator or co-investigator

Investigators

Sponsor
Yamazaki Kana

Similar Trials